|
|
Volumn 11, Issue 3, 2012, Pages 171-172
|
|
Advancing the development of tuberculosis therapy
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE;
AZD 5847;
BEDAQUILINE;
DELAMANID;
ETHAMBUTOL;
GATIFLOXACIN;
ISONIAZID;
MOXIFLOXACIN;
N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE;
PLACEBO;
PYRAZINAMIDE;
RIFAMPICIN;
RIFAPENTINE;
SUTEZOLID;
TUBERCULOSTATIC AGENT;
UNCLASSIFIED DRUG;
BACTERICIDAL ACTIVITY;
DRUG MEGADOSE;
DRUG SAFETY;
DRUG SUBSTITUTION;
DRUG TOLERABILITY;
DRUG TREATMENT FAILURE;
DRUG WITHDRAWAL;
EXTENSIVELY DRUG RESISTANT TUBERCULOSIS;
HUMAN;
MULTIDRUG RESISTANT TUBERCULOSIS;
MYCOBACTERIUM TUBERCULOSIS;
NONHUMAN;
PRIORITY JOURNAL;
RELAPSE;
REVIEW;
TUBERCULOSIS;
ANIMALS;
ANTITUBERCULAR AGENTS;
CLINICAL TRIALS AS TOPIC;
DRUG DISCOVERY;
HUMANS;
MYCOBACTERIUM TUBERCULOSIS;
QUINOLINES;
TUBERCULOSIS;
|
|
EID: 84857776155
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3694 Document Type: Review |
|
Times cited : (52)
|
|
References (5)
|
